Guotai Junan I (01788) Announces Profit Joy: Expected annual net profit is between HK$12.80 billion and HK$13.80 billion, a year-on-year increase of 265% to 293%.

07:25 26/01/2026

Guotai Junan International (01788) announced that it expects the Group's net profit for the year ending December 31, 2025 to be between 1.28 billion and 1.38 billion Hong Kong dollars, a significant increase of 265% to 293% compared to the net profit in 2024 of approximately 351 million Hong Kong dollars. The main reason for this expected growth is the significant increase in core business income such as corporate financing, wealth management, asset management, trading, and investment, with particularly outstanding performance in equity financing and brokerage business.

Guotai Junan International (01788) announced that the expected net profit of the group for the year ending December 31, 2025 is between 1.28 billion and 1.38 billion Hong Kong dollars, a significant increase of 265% to 293% compared to the net profit in 2024 of approximately 351 million Hong Kong dollars. The main reason for this expected growth is the comprehensive and significant increase in core business revenues such as corporate financing, wealth management, asset management, and trading and investment. Among them, equity financing and brokerage business performance is particularly outstanding.

SKYMISSION GP (01429) resumed trading on January 26th.

Pre-market report on A shares | Commercial aerospace welcomes three major positives! Musk calls out again, surging over 400%! Two bullish stocks will be suspended today.

CITIC SEC: Accelerating the "Four Modernizations" of pharmaceutical retailing, beneficial for policy-based classification treatment and separation of medicine and business.

SKYMISSION GP (01429) resumed trading on January 26th.

Pre-market report on A shares | Commercial aerospace welcomes three major positives! Musk calls out again, surging over 400%! Two bullish stocks will be suspended today.

CITIC SEC: Accelerating the "Four Modernizations" of pharmaceutical retailing, beneficial for policy-based classification treatment and separation of medicine and business.